RT期刊文章SR电子T1与IV卡马西平的连续性护理:维持治疗的病例报告(P5.235)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P5.235 VO 88是16补充A1马丁·j·布罗迪A1帕维尔•克莱恩A1喇曼San首页kar A1巴里·e·托尔博特Gidal A1 Dwain年2017 UL //www.ez-admanager.com/content/88/16_Supplement/P5.235.abstract AB目的:描述一个案例报告,说明维护卡马西平治疗的重要性。背景:批准在1970年代中期以来,口服卡马西平已广泛应用在很多年前开始治疗的患者,它仍然是一个负担得起的选择对病人从较低的社会经济团体和/或那些高额的保险计划。尽管卡马西平是一种已知的细胞色素P450 (CYP)同功酶的诱导物,开处方者可能不知道在撤军毒性的风险。下情况下口服卡马西平是暂时行不通,连续性静脉卡马西平的护理配方(IV-CBZ)将比为了保持de-induction发作控制和避免可能的影响。设计/方法:病例报告的卡马西平(卡马西平)de-induction被描述。结果:51岁女性历史的癫痫、风湿性心脏病、二尖瓣瓣膜,和不受控制的癫痫症状经历1 - 2其次广义发作/月尽管使用苯妥英、卡马西平;病人同时接受地高辛和华法林。苯妥英慢慢收回,病人是维护在拉莫三嗪(150毫克b.i.d。)和卡马西平不断更新的配方(400毫克b.i.d)。三年后,病人有经验的共济失调和被称为全科医生到另一个医院,那时卡马西平几个月前在门诊中撤出。病人死亡后不久进入急诊室休克和严重的背痛。死因未识别的腹膜后出血是由于华法令阻凝剂毒性次要de-induction卡马西平后撤退。结论:管理伴随CBZ-treated患者的治疗是很困难的,改变一个稳定剂量的卡马西平可以影响其他药物。 The use of IV-CBZ can maintain patients’ stable CBZ treatment when oral administration is impracticable, avoiding untoward and potentially dangerous side effects of CBZ de-induction.Study Supported by: Lundbeck LLCDisclosure: Dr. Brodie has received personal compensation for activities with UCB Pharma, Eisai Ltd, Lundbeck Inc., GW Pharmaceuticals, Bial, GlaxoSmithKline, Sanofi Aventis, and Abbot for grants/research support, honoraria, consulting fees, or speakers bureau. Dr. Klein has received personal compensation for activities with Eisai, Sunovion, and UCB Inc. as a speaker. Dr. Klein has received personal compensation for activities with Lundbeck LLC, Sunovion, and UCB Inc. as an advisory board member. Dr. Klein has received research support from Eisai and Lundbeck LLC. Dr. Sankar has received personal compensation for activities with Lundbeck, Eisai, UCB Pharma, Supernus, Sunovion, Upsher-Smith, and Cyberonics. Dr. Gidal has received personal compensation for activities with UCB, Eisai, and Sunovion for speaking engagements. Dr. Gidal has received personal compensation from UCB, Eisai, Sunovion, Upsher-Smith, Lundbeck LLC, and SK-Bioscience as a consultant. Dr. Tolbert has received personal compensation for activities with Lundbeck LLC.